Systemic administration of low-dose naltrexone increases bone mass due to blockade of opioid growth factor receptor signaling in mice osteoblasts

Life Sci
01 May 2019
https://pubmed.ncbi.nlm.nih.gov/30930116/

Dose Escalation of Naltrexone to Reduce Stress Responses Associated With Opioid Antagonist Induction: A Double-blind Randomized Trial

J Addict Med
May/Jun 2020
https://pubmed.ncbi.nlm.nih.gov/31609865/

Context: To describe the role of opioid antagonist induction in reducing stress response and withdrawal symptoms.

Transition of Patients With Opioid Use Disorder From Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens

American Journal on Addictions
04 April 2020
https://onlinelibrary.wiley.com/doi/full/10.1111/ajad.13024

Dickson Chemist developed a new formulation of LDN which will hopefully improve the outcomes for patients. This new formulation is a more concentrated liquid in the form of drops which are administered under the tongue and absorbed directly from the mucosal lining of the mouth. This sublingual route produces a more rapid absorption bypassing the liver and digestive tract. There are several potential advantages to this, the drug may be more effective and will not be affected by the presence of food stuffs or the hostile environment of the gut.